NASDAQ:NVCNNeovasc Stock Price, Forecast & News

Neovasc's stock was trading at $2.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVCN shares have increased by 5.4% and is now trading at $2.33.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neovasc.

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Neovasc.

Neovasc Inc (NASDAQ:NVCN) issued its quarterly earnings results on Thursday, August, 6th. The medical equipment provider reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.22.
View Neovasc's earnings history.

Shares of Neovasc reverse split on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

Neovasc issued an update on its second quarter 2020 IntraDay earnings guidance on Monday, July, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $295K - 295K.

3 Wall Street analysts have issued 1 year price objectives for Neovasc's shares. Their forecasts range from $3.00 to $15.00. On average, they anticipate Neovasc's stock price to reach $7.67 in the next year. This suggests a possible upside of 229.0% from the stock's current price.
View analysts' price targets for Neovasc.

Media headlines about NVCN stock have trended very positive on Monday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neovasc earned a news impact score of 3.2 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Neovasc.

Neovasc saw a increase in short interest in July. As of July 31st, there was short interest totaling 195,500 shares, an increase of 5.4% from the July 15th total of 185,500 shares. Based on an average daily volume of 297,700 shares, the days-to-cover ratio is presently 0.7 days. Currently, 1.4% of the shares of the stock are short sold.
View Neovasc's Short Interest.

Some companies that are related to Neovasc include Venus Concept (VERO), PAVmed (PAVM), BeyondAirInc . (XAIR), Spectral Medical (EDTXF), Pro-Dex (PDEX), Neuronetics (STIM), SANUWAVE Health (SNWV), Nephros (NEPH), BRAINSWAY LTD/S (BWAY), Titan Medical (TMDI), Nephros (NEPHD), DarioHealth (DRIO), AIT Therapeutics (AITB), Sintx Technologies (SINT) and Sensus Healthcare (SRTS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Protalix Biotherapeutics (PLX), 22nd Century Group (XXII), Immune Pharmaceuticals (IMNP), Advanced Micro Devices (AMD) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock is owned by a variety of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.40%).

NVCN stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $2.33.

Neovasc has a market capitalization of $25.93 million and generates $2.09 million in revenue each year. The medical equipment provider earns $-35,130,000.00 in net income (profit) each year or ($5.05) on an earnings per share basis. Neovasc employs 98 workers across the globe.

The official website for Neovasc is www.neovasc.com.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]